Annovis Bio, Inc.
ANVS
$1.25
-$0.06-4.23%
NYSE
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
9/8/2026
-
Zacks Investment Research
9/4/2026
-
TipRanks
9/3/2026
-
MarketBeat
8/30/2026
-
The Cerbat Gem
8/29/2026
-
MarketBeat
8/27/2026
-
TipRanks: TheFly
8/26/2026
-
The Cerbat Gem
8/25/2026
-
Globe Newswire
Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP)
8/19/2026
-
TipRanks
8/19/2026
-
TipRanks
8/18/2026
-
TipRanks
8/18/2026
-
The Cerbat Gem
8/18/2026
-
MarketBeat
8/14/2026
-
MarketBeat
8/14/2026
-
MarketBeat
8/14/2026
-
Globe Newswire
8/4/2026
-
MarketBeat
8/1/2026
-
MarketBeat
7/11/2026
-
The Cerbat Gem
7/11/2026
-
MarketBeat
7/9/2026
-
The Cerbat Gem
7/9/2026
-
MarketBeat
7/8/2026
-
TipRanks
7/7/2026
-
TipRanks: TheFly
7/7/2026
-
TipRanks: TheFly
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
--
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Friday, August 14, 2026
Period Date
Tuesday, June 30, 2026
Next Filing
Week of Nov 9 and 13 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
484 875 3192
Address
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
Suite 225
Malvern, PA 19355
Country
Year Founded
Business Description
Sector
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 3...
more